Sera from patients with scleroderma inhibit fibroblast micromotions monitored electrically

Journal of Rheumatology

Volumn 26, Issue 6, 1999, Pages 1312-1317

  Huang, Chien Ning ^b   Lo, Chun Min ^b   Hsu, Tsai Ching ^b   Tsay, Gregory J ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b NONE

Author keywords

Electrical cell substrate impedance sensing; Fibroblast; Micromotions; Scleroderma

Indexed keywords

ADULT; AGED; ARTICLE; BIOSENSOR; CASE REPORT; CELL ADHESION; CELL MIGRATION; CELL MOTION; CELL STRUCTURE; ELECTRIC RESISTANCE; FEMALE; FIBROBLAST; HUMAN; IMPEDANCE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032995907     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Leroy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
2. Giaever I, Keese CR. Micromotion of mammalian cells measured electrically. Proc Natl Acad Sei USA 1991;88:7896-900.
3. Heckmann M, Krieg T. Biological and pharmacological modulations of fibroblast functions. Skin Pharmacol 1989;2:125-37.
4. Whiteside TL, Patricia MF, Buckingham RB. Heterogeneous synthetic phenotype of cloned scleroderma fibroblasts may be due to aberrant regulation in the synthesis of connective tissues. Arthritis Rheum 1988;31:1221-9.
5. Gay S, Jones RE Jr, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989;92:301-3.
6. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Transforming growth factor-β increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 1987;79:1285-8.
7. Giaever I, Keese CR. Monitoring fibroblast behavior in tissue culture with an applied electric field. Proc Natl Acad Sei USA 1984;81:3761-4.
8. Kowolenko M, Keese CR, Lawrence DA, Giaever I. Measurement of macrophage adherence and spreading with weak electric field. J Immunol Methods 1990;127:71-7.
9. Giaever I, Keese CR. A morphological biosensor for mammalian cells. Nature 1993;366:591-2.
10. Lo CM, Keese CR, Giaever I. Monitoring motion of confluent cells in tissue culture. Exp Cell Res 1993;204:102-9.
11. Lo CM, Keese CR, Giaever I. pH changes in pulsed CO2 incubators cause periodic changes in cell morphology. Exp Cell Res 1994;213:391-7.
12. Subcommittee for Scleroderma Criteria of the American Rheumatism Association and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:271-7.
14. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjögren's syndrome: results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
15. Lo CM, Keese CR, Giaever I. Impedance analysis of MDCK cells measured by electric cell-substrate impedance sensing. Biophys J 1995;69:2800-7.
16. Kawaguchi Y, Kitani A, Hera M, et al. Cytokine regulation of prolyl 4-hydroxylase production in skin fibroblast culture from patients with systemic sclerosis: contribution to collagen synthesis and fibrosis. J Rheumatol 1992;19:1195-201.
17. Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995;270:3423-8.
18. Gillery P, Maquart X, Le Corre Y, Kalis B, Borel JP. Variability in the retraction of collagen lattices by scleroderma fibroblasts -relationship to protein synthesis and clinical data. Clin Exp Dermatol 1991;16:324-30.
19. Majewski S, Hunzelmann N, Schirren CG, Mauch C, Aumailley M, Krieg T. Increased adhesion of fibroblasts from patients with scleroderma to extracellular matrix components: in vitro modulation by IFN-γ but not by TGF-β. J Invest Dermatol 1992;98:86-91.
20. LeRoy EC, Kahaleh MB, Mercurio S. A fibroblast mitogen present in scleroderma but not control sera: inhibition by proteinase inhibitors. Rheumatol Int 1983;3:35-9.
21. Goldring MB, Krane SM. Modulation by recombinant interleukin 1 of synthesis of type I and III collagens and associated procollagen mRNA levels in cultured human cells. J Biol Chem 1987;262:16724-9.
22. Kahaleh MB, Fan PS. Effect of cytokines on the production of endothelin by endothelial cells. Clin Exp Rheum 1997;15:163-7.
23. Kikuchi K, Kadono T, Furue M, Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997;108:281-4.
24. Smith TJ, Wang HS, Hogg MG, Henrikson RC, Keese CR, Giaever I. Prostaglandin E2 elicits a morphological change in cultured orbital fibroblasts from patients with Graves ophthalmopathy. Proc Natl Sci USA 1994;91:5094-8.
25. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon γ levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
26. Kantor TV, Friberg D, Medsger TA Jr, Buckingham RB, Whiteside TL. Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol 1992;65:278-85.
27. Kahaleh MB, Fan PS. Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 1997;83:32-40.
28. Elias JA. Tumor necrosis factor interacts with interleukin-1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandin-dependent and -independent mechanisms. Am Rev Respir Dis 1988;138:652-8.
29. Tsay GJ, Fann RH, Hwang J. Specificity of anti-scl-70 antibodies in scleroderma: increased sensitivity of detection using purified DNA topoisomerase I from calf thymus. J Rheumatol 1990;17:1314-9.
30. Tsay GJ, Lan JL, Li SY. Chromosome studies in systemic sclerosis with consideration of antibodies to topoisomerase I. Ann Rheum Dis 1992;51:624-6.
31. Emerit I, Levy A, Housset E. Breakage factor in systemic sclerosis and protector effect of L-cysteine. Hum Genet 1974;25:221-6.
32. Drenk F, Deicher HRG. Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis. J Rheumatol 1988;15:468-74.
33. Gillery P, Serpier H, Polette M, et al. Gamma-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice cultures of normal and scleroderma skin fibroblasts. Euro J Cell Biol 1992;57:244-53.
34. Takehara K, Soma Y, Igarashi A, Kikuchi K, Moro A, Ishibashi Y. Response of scleroderma fibroblasts to various growth factors. Arch Dermatol Res 1991;283:461-4.
35. Duncan MR, Hasan A, Berman B. Oncostatin M stimulates collagen and glycosaminoglycan production by cultured normal dermal fibroblasts: insensitivity of sclerodermal and keloidal fibroblasts. J Invest Dermatol 1995;104:128-33.